With unusual bipartisan support, a new piece of legislation of about 1,000 pages was signed into law on Dec. 13, 2016 – the 21st Century Cures Act. The Act will allocate about $6 billion to a variety of medically related needs. While the bill has received both applause and criticism from various interest groups, there are many relevant points to mention.
National Institutes of Health (NIH) Funding: The Act provides billions of dollars of new funding to the NIH for research into diseases such as cancer and Alzheimer’s.
Health Information Technology: Recognizing current IT challenges, the Act allows for reduction of some documentation burden and creates an electronic medical record (EMR) tool to assist with EMR-related decisions. In addition, it gives authority to the U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG) to investigate claims of IT sharing obstacles.
Site-of-Service Cost Disclosure: The Centers for Medicare & Medicaid Services (CMS) will create a website with a guide to estimate payment amounts for outpatient surgeries, along with the beneficiary’s liability amount.
Medicare Part A Inpatient/Part B Outpatient Surgical Code Comparator: This is a juxtaposition of the inpatient surgical codes to related outpatient codes for 10 common procedures.
Socio-Economic Status Adjustment for Readmissions: This is a risk adjustment calculation meant to account for various socio-economic factors, initially using a temporary method, but eventually requiring a permanent methodology.
Medicare Advantage for ESRD: This is an option for MA plan enrollment for ESRD patients as of 2021.
Opioid Abuse Prevention: Designates funds for opioid abuse prevention and therapy programs.
Ambulatory Surgical Center (ASC) MACRA Exclusion: Temporarily excludes providers that primarily practice in ASCs from Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Merit-Based Incentive Payment System (MIPS) requirements.
Telehealth: Requires CMS to provide information on expanding telehealth coverage, along with comparative information for commercial insurers.
“Breakthrough” Technologies and Combination Products: A program will be established for expediting approval for breakthrough technologies. Certain criteria will be put in place to determine validity of the “breakthrough” label. A dedicated center for combination products is to be created to streamline the review of new products.
Antimicrobial Stewardship: The Food and Drug Administration (FDA) shall continue to monitor antimicrobial resistance. For a serious or life-threatening infection, the FDA may approve a new agent in a limited patient cohort, even with a lack of evidence to establish a satisfactory benefit/harm ratio in a broader population.
Experience Data Gathering: Prior to granting approval, the FDA will be seeking broader input regarding the experience of patients, beyond that of just the manufacturer. The experience data can be derived from any person or entity.
Qualification of Drug Development Tools: Establishes a process for the qualification of new drug/biologic development tools. The purpose is to encourage the development of genetically targeted agents for rare diseases. It includes expansion of the process for grants and vouchers for priority review of drugs for such conditions.
Trial Design and Level of Evidence: The FDA will now consider inclusion of sources other than randomized controlled trials (RCTs) for new drug reviews. A new set of guidelines will be developed utilizing broad input from industry sources, academic institutions, professional societies, patient advocacy/consumer groups, disease research foundations, etc.
Patient Access to Therapies: Developers of investigational therapies for serious diseases will make available policies for inclusion of patients on a publicly accessible website. Applications for regenerative therapy, such as cell therapy and human cell/tissue products, will be eligible for an accelerated review.
While there is much to like in this Act, its fate is unknown with the new Trump administration having taken office. The changes to the FDA approval process should also scare the heck out of every doctor who is tired of the constant TV ads for medications for toenail fungus, lung cancer, and of course, erectile dysfunction.
While the president has been talking a lot about high drug prices, he is clearly pro-business and anti-regulation. The Act will allow drugs to be approved based on data other than controlled clinical trials, perhaps only requiring drug companies to prove safety with no requirement for efficacy data. Scary times could be ahead.
Picture this: You are driving through an area you don’t know well. It is a cold day. You stop to get gas. You fill the
Federal health officials have announced the launch of the Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) initiative. The announcement was framed as a decisive step
Please log in to your account to comment on this article.
Sepsis sequencing continues to challenge even experienced coding and CDI professionals, with evolving guidelines, documentation gaps, and payer scrutiny driving denials and data inconsistencies. In this webcast, Payal Sinha, MBA, RHIA, CCDS, CDIP, CCS, CCS-P, CCDS-O, CRC, CRCR, provides clear guideline-based strategies to accurately code sepsis, severe sepsis, and septic shock, assign POA indicators, clarify the relationship between infection and organ dysfunction, and align documentation across teams. Attendees will gain practical tools to strengthen audit defensibility, improve first-pass accuracy, support appeal success, reduce denials, and ensure accurate quality reporting, empowering organizations to achieve consistent, compliant sepsis coding outcomes.
Expert presenters Kathy Pride, RHIT, CPC, CCS-P, CPMA, and Brandi Russell, RHIA, CCS, COC, CPMA, break down complex fracture care coding rules, walk through correct modifier application (-25, -57, 54, 55), and clarify sequencing for initial and subsequent encounters. Attendees will gain the practical knowledge needed to submit clean claims, ensure compliance, and stay one step ahead of payer audits in 2026.
Accurately determining the principal diagnosis is critical for compliant billing, appropriate reimbursement, and valid quality reporting — yet it remains one of the most subjective and error-prone areas in inpatient coding. In this expert-led session, Cheryl Ericson, RN, MS, CCDS, CDIP, demystifies the complexities of principal diagnosis assignment, bridging the gap between coding rules and clinical reality. Learn how to strengthen your organization’s coding accuracy, reduce denials, and ensure your documentation supports true medical necessity.
Denials continue to delay reimbursement, increase administrative burden, and threaten financial stability across healthcare organizations. This essential webcast tackles the root causes—rising payer scrutiny, fragmented workflows, inconsistent documentation, and underused analytics—and offers proven, data-driven strategies to prevent and overturn denials. Attendees will gain practical tools to strengthen documentation and coding accuracy, engage clinicians effectively, and leverage predictive analytics and AI to identify risks before they impact revenue. Through real-world case examples and actionable guidance, this session empowers coding, CDI, and revenue cycle professionals to shift from reactive appeals to proactive denial prevention and revenue protection.
In this timely session, Stacey Shillito, CDIP, CPMA, CCS, CCS-P, CPEDC, COPC, breaks down the complexities of Medical Decision Making (MDM) documentation so providers can confidently capture the true complexity of their care. Attendees will learn practical, efficient strategies to ensure documentation aligns with current E/M guidelines, supports accurate coding, and reduces audit risk, all without adding to charting time.
Join Ronald Hirsch, MD, FACP, CHCQM for The PEPPER Returns – Risk and Opportunity at Your Fingertips, a practical webcast that demystifies the PEPPER and shows you how to turn complex claims data into actionable insights. Dr. Hirsch will explain how to interpret key measures, identify compliance risks, uncover missed revenue opportunities, and understand new updates in the PEPPER, all to help your organization stay ahead of audits and use this powerful data proactively.
Stay ahead of the 2026-2027 audit surge with “Top 10 Audit Targets for 2026-2027 for Hospitals & Physicians: Protect Your Revenue,” a high-impact webcast led by Michael Calahan, PA, MBA. This concise session gives hospitals and physicians clear insight into the most likely federal audit targets, such as E/M services, split/shared and critical care, observation and admissions, device credits, and Two-Midnight Rule changes, and shows how to tighten documentation, coding, and internal processes to reduce denials, recoupments, and penalties. Attendees walk away with practical best practices to protect revenue, strengthen compliance, and better prepare their teams for inevitable audits.
As AI reshapes healthcare compliance, the risk of biased outputs and opaque decision-making grows. This webcast, led by Frank Cohen, delivers a practical Four-Pillar Governance Framework—Transparency, Accountability, Fairness, and Explainability—to help you govern AI-driven claim auditing with confidence. Learn how to identify and mitigate bias, implement robust human oversight, and document defensible AI review processes that regulators and auditors will accept. Discover concrete remedies, from rotation protocols to uncertainty scoring, and actionable steps to evaluate vendors before contracts are signed. In a regulatory landscape that moves faster than ever, gain the tools to stay compliant, defend your processes, and reduce liability while maintaining operational effectiveness.
Happy National Doctor’s Day! Learn how to get a complimentary webcast on ‘Decoding Social Admissions’ as a token of our heartfelt appreciation! Click here to learn more →
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 1 with code CYBER25
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
